
SpyGlass Pharma, Inc.: updates and filings
Price
$30.43
November 20, 2026Market cap $1.0B
What Ploutos Investor adds for SpyGlass Pharma
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
October 2026
August 2026
May 2026
March 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operations, other material eventsForm8-K
- Oct 19, 2026Other material eventsForm8-K
- Oct 1, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operationsForm8-K
- Mar 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 26, 2026Results of operationsForm8-K
- Mar 9, 2026Other material eventsForm8-K
- Feb 17, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 17, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Feb 13, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Feb 13, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Feb 13, 2026Officer or director changeForm8-K
- Feb 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 10, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Feb 9, 2026Officer or director change, amended articles or bylaws, Regulation FD disclosureForm8-K
- Feb 6, 2026Shares registered for employeesFormS-8
- Feb 5, 2026Exchange certification of a listingFormCERT
- Feb 5, 2026Securities listed on an exchangeForm8-A12B
- Jan 30, 2026FilingFormEFFECT
- Jan 29, 2026Correspondence with the SECFormCORRESP
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations, other material events | Document |
| Oct 19, 2026 | 8-K | Other material events | Document |
| Oct 1, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations | Document |
| Mar 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 26, 2026 | 8-K | Results of operations | Document |
| Mar 9, 2026 | 8-K | Other material events | Document |
| Feb 17, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 17, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Feb 13, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Feb 13, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Feb 13, 2026 | 8-K | Officer or director change | Document |
| Feb 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 10, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Feb 9, 2026 | 8-K | Officer or director change, amended articles or bylaws, Regulation FD disclosure | Document |
| Feb 6, 2026 | S-8 | Shares registered for employees | Document |
| Feb 5, 2026 | CERT | Exchange certification of a listing | Document |
| Feb 5, 2026 | 8-A12B | Securities listed on an exchange | Document |
| Jan 30, 2026 | EFFECT | Filing | Document |
| Jan 29, 2026 | CORRESP | Correspondence with the SEC | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 5, 2019.
The full analysis
What do SpyGlass Pharma's filings show?
The filings are where every one of SpyGlass Pharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.